Pages

▼
Saturday, July 4, 2026

Allogeneic CD7-Targeted CAR-T Cell (RD13-02) Starts Second Phase-I Clinical Trial

›
RD13-02 uses specially engineered immune cells designed to remove certain immune cells believed to drive the autoimmune attack that damages ...
1 comment:
Tuesday, June 16, 2026

SAB-142 From SAb Biotherapeutics Starts a Phase II Trial (SAFEGUARD)

›
Back in April, I blogged about a Phase-II study called "Anti-Thymocyte Globulin and Verapamil Start A Phase-2 Clinical Trial" (NCT...
Thursday, June 4, 2026

Rezpegaldesleukin (or NKTR-358) Starts A Phase-IIΔ Clinical Trial on Honeymooners (RESET T1D)

›
A new clinical trial is testing Rezpegaldesleukin, also known as NKTR-358, or REZPEG, as a potential treatment to slow or stop T1D in honeym...
Thursday, May 14, 2026

Phase-I Clinical Trial of Islet Transplantation Into Eye

›
Pancreatic islet transplantation is an approach designed to restore the body’s ability to produce insulin by transplanting beta cells (insul...
Thursday, April 30, 2026

Anti-Thymocyte Globulin and Verapamil Start A Phase-2 Clinical Trial

›
Researchers at the University of Florida are launching a new Phase 2 clinical trial to evaluate a combination therapy for individuals recent...
3 comments:
Wednesday, April 8, 2026

GentiBio starts a Phase-I Clinical Trial on GNTI-122 in Honeymooners (POLARIS)

›
GentiBio, Inc. is sponsoring a clinical trial known as POLARIS, which aims to evaluate a cell therapy called GNTI-122 in honeymoon adults.  ...
Monday, February 23, 2026

Results From An Omega-3 and Vitamin D Clinical Trial In People With Long Standing T1D

›
Researchers at the University of Miami are exploring whether a combination of two well-known supplements—omega-3 fatty acids and vitamin D—m...
1 comment: